The global prostate cancer therapeutics market was valued at USD 13.4 billion in 2024, and it is projected to expand at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. This anticipated growth is primarily attributed to several key factors, including the increasing incidence of prostate cancer worldwide, advancements in early detection through improved screening and diagnostic technologies, and supportive government initiatives that promote the development and approval of new treatments.

In recent years, the integration of cutting-edge technologies such as bioinformatics and computational biology has significantly enhanced the landscape of therapy development. Leading industry players are utilizing sophisticated techniques, including proteome profiling and genome sequencing, to innovate and refine therapeutic solutions. A notable example is a phase III clinical trial conducted in 2022, which involved more than 4,000 male participants. This trial assessed the efficacy of Olaparib and employed tumor genomic testing to identify patients who would most benefit from the treatment.

The COVID-19 pandemic had a profound impact on the prostate cancer therapeutics sector. It disrupted routine doctor-patient consultations, limited patient access to essential cancer treatments, and influenced clinical decision-making processes. Additionally, the pandemic exacerbated existing social and economic inequalities, thereby widening disparities in healthcare access and outcomes. Patients suffering from prostate cancer experienced greater vulnerability, facing an elevated risk of severe complications and higher mortality rates from COVID-19 compared to individuals without cancer.

Key industry stakeholders continue to focus on research and development aimed at introducing advanced and innovative treatment options. Numerous pharmaceutical companies have promising candidates in their development pipelines, many of which are expected to be launched during the forecast period. For instance, in March 2022, Merck initiated the keylynk-010 trial, which evaluates the combination of Keytruda and Lynparza in patients diagnosed with metastatic castration-resistant prostate cancer.

Government initiatives are playing a pivotal role in accelerating market growth by supporting the approval and distribution of novel therapies. In March 2022, the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617, a novel treatment for metastatic prostate cancer. Developed by the Society of Nuclear Medicine and Molecular Imaging, this therapy utilizes PET scans to detect and treat patients whose cancers express PSMA (prostate-specific membrane antigen). Clinical studies have demonstrated that this treatment can reduce the risk of death by as much as 38%.

Despite the advancements in targeted therapies, their high cost remains a major barrier to widespread accessibility. Targeted treatments are often prohibitively expensive for the average patient. According to a report published by the American Society of Clinical Oncology in May 2021, the United States leads the world in cancer drug prices, with costs that are more than twice as high as those in Europe and two to six times higher than in other parts of the world.

Detailed Segmentation:

Drug Class Insights

The hormonal therapy drug class dominated the market in 2024, accounting for an 88.6% revenue share. This therapy mainly includes luteinizing hormone-releasing hormone (LHRH) antagonists and anti-androgens. Xtandi is one of the most widely used drugs, not only due to an increase in prostate cancer treatments but also because patients are using it for longer periods,

Distribution Channel Insights

The hospital pharmacies segment dominated the market and accounted for the largest revenue share of 48.2% in 2024. Hospital pharmacies and pharmacists are important market participants because they manage pharmaceuticals in a critical hospital setting that necessitates quick access to drugs and supplies. 

Regional Insights

North America prostate cancer therapeutics market dominated the global market with a revenue share of 40.8% in 2024 due to an increase in the disease's prevalence and a strong need for prostate cancer therapeutic products in the region.

Key Prostate Cancer Therapeutics Company Insights

Some of the key companies operating in prostate cancer therapeutics are Johnson & Johnson Services, Inc., Astellas Pharma Inc., and Eli Lilly and Company. These companies are growing their market presence by launching new products, collaborating, and adopting various other strategies.

• Johnson & Johnson Services, Inc. is a key player in the prostate cancer therapeutics market, offering advanced treatment options focused on improving patient outcomes. The company’s portfolio includes innovative hormone therapies and targeted treatments designed for different stages of prostate cancer. With a strong emphasis on research and development, Johnson & Johnson explores novel therapeutic approaches, such as next-generation androgen receptor inhibitors and combination therapies. Its commitment to advancing oncology treatments supports the development of new options for prostate cancer care worldwide.
• Astellas Pharma Inc. provides treatments designed to address various stages of the disease. The company develops androgen receptor inhibitors and targeted therapies to improve treatment outcomes. Focusing on research, Astellas Pharma conducts clinical trials to evaluate new therapeutic combinations and personalized approaches. Its work in oncology research contributes to the availability of advanced options for prostate cancer treatment.

Key Prostate Cancer Therapeutics Companies:

The following are the leading companies in the prostate cancer therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi
• Ipsen Pharma
• Bayer AG
• AstraZeneca
• Bausch Health Companies Inc.
• Merck & Co., Inc.
• Pfizer Inc.

Recent Developments

• In April 2024, Astellas Pharma Inc. received approval from the European Commission to extend XTANDI (enzalutamide) use. The decision permits its use alone or with androgen deprivation therapy in adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are not suitable for salvage radiotherapy.
• In February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 trial evaluating TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in men with metastatic castration-resistant prostate cancer (mCRPC). The combination significantly reduced the risk of disease progression or death by 37% compared to placebo plus XTANDI. These findings suggest that adding TALZENNA to XTANDI may offer a promising treatment option for patients with mCRPC, addressing an unmet need in advanced prostate cancer therapy. 

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.